Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Mentice Yönetim

Yönetim kriter kontrolleri 1/4

Mentice's CEO'su Göran Malmberg, Mar2008 tarihinde atandı, in görev süresi 16.58 yıldır. şirketin hisselerinin 2.78% doğrudan sahiptir ve bu hisselerin değeri € 1.71M dir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.9 yıl ve 5.2 yıldır.

Anahtar bilgiler

Göran Malmberg

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	16.6yrs
CEO sahipliği	2.8%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	5.2yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Göran Malmberg'un ücretlendirmesi Mentice'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-SEK 10m
Mar 31 2024	n/a	n/a	-SEK 26m
Dec 31 2023	n/a	n/a	-SEK 3m
Sep 30 2023	n/a	n/a	SEK 2m
Jun 30 2023	n/a	n/a	-SEK 6m
Mar 31 2023	n/a	n/a	-SEK 25m
Dec 31 2022	n/a	n/a	-SEK 31m
Sep 30 2022	n/a	n/a	-SEK 37m
Jun 30 2022	n/a	n/a	-SEK 36m
Mar 31 2022	n/a	n/a	-SEK 24m
Dec 31 2021	SEK 4m	SEK 4m	-SEK 29m
Sep 30 2021	n/a	n/a	-SEK 22m
Jun 30 2021	n/a	n/a	-SEK 15m
Mar 31 2021	n/a	n/a	-SEK 21m
Dec 31 2020	SEK 4m	SEK 3m	-SEK 13m
Sep 30 2020	n/a	n/a	-SEK 9m
Jun 30 2020	n/a	n/a	-SEK 17m
Mar 31 2020	n/a	n/a	-SEK 17m
Dec 31 2019	SEK 6m	SEK 5m	-SEK 21m

Tazminat ve Piyasa: Göran şirketinin toplam tazminatının German pazarındaki benzer büyüklükteki şirketlerle karşılaştırıldığında makul olup olmadığını tespit etmek için yeterli veri yok.

Tazminat ve Kazançlar: Göran şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Göran Malmberg (65 yo)

16.6yrs

Görev süresi

SEK 4,465,000

Tazminat

Mr. Goran Malmberg serves as Group Chief Executive Officer and President at Mentice AB. Mr. Malmberg had been the Chief Executive Officer and President of Mentice AB since March 2008. Mr. Malmberg has exte...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Göran Malmberg	Group CEO & President	16.6yrs	SEK 4.47m	2.78% € 1.8m
Ulrika Voksepp	Chief Financial Officer	less than a year	Veri yok	Veri yok
Jonatan Sjostrom	Chief Operating Officer	1.1yrs	Veri yok	Veri yok
Henrik Storm	Chief Technology Officer	9.8yrs	Veri yok	Veri yok
Martin Harris	Vice President of Marketing	less than a year	Veri yok	Veri yok
Matar Dakhil	Executive Vice President of Business Development	no data	Veri yok	Veri yok
Edward Fält	Chief Strategy Officer	less than a year	Veri yok	Veri yok
Stacy Hammar	Corporate Marketing Manager of Medical Device	no data	Veri yok	Veri yok
Dominic Steffel	Senior Product Manager	no data	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: MN2 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Gosta Johannesson	Director	5.2yrs	SEK 170.00k	Veri yok
Denis Gestin	Independent Director	5.2yrs	SEK 170.00k	Veri yok
Lawrence Howell	Director	13.8yrs	Veri yok	34.01% € 22.4m
Eola Runsten	Independent Director	4.4yrs	SEK 170.00k	Veri yok
David Ballard	Independent Director	5.2yrs	SEK 170.00k	Veri yok
Johann Koss	Independent Director	9.8yrs	SEK 100.00k	Veri yok
Magnus Nilsson	Independent Chairman of the Board	1.8yrs	SEK 360.00k	Veri yok

5.2yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MN2 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.2 yıldır).

Mentice Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Director recently bought €71k worth of stock

Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024

Mentice AB (Publ) Announces Board Appointments

Mentice AB (publ), Annual General Meeting, May 23, 2024

Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023

Mentice AB (publ) Announces Chief Financial Officer Changes

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: kr0.67 (vs kr0.064 in 2Q 2023)

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

Mentice AB (publ) to Report Fiscal Year 2023 Final Results on Apr 24, 2024

Full year 2023 earnings released: kr0.11 loss per share (vs kr1.22 loss in FY 2022)

New minor risk - Market cap size

New major risk - Share price stability

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice Receives FDA 510(K) Clearance for Ankyras

Mentice AB (publ) (OM:MNTC) agreed to acquire All substantial assets of Biomodex from SIMARATO SAS for €0.2 million.

Director recently bought €71k worth of stock

Mentice (publ) Appoints Ulrika Drotz Voksepp as New Chief Financial Officer, Effective January 2, 2024

Mentice AB (Publ) Announces Board Appointments

Third quarter 2023 earnings released

Mentice AB (publ), Annual General Meeting, May 23, 2024

Mentice AB (publ) to Report First Half, 2024 Results on Jul 23, 2024

Mentice AB (Publ) Appoints of Jonatan Sjöström to Its Executive Management Group as Chief Operating Officer, Effective from September 14, 2023

New minor risk - Market cap size

Mentice AB (publ) Announces Chief Financial Officer Changes

Second quarter 2023 earnings released: EPS: kr0.06 (vs kr0.72 loss in 2Q 2022)

Insufficient new directors

Mentice AB (publ) Announces Resignation of Gunilla Andersson as Chief Financial Officer

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Full year 2022 earnings released: kr1.22 loss per share (vs kr1.18 loss in FY 2021)

Third quarter 2022 earnings released: kr0.30 loss per share (vs kr0.29 loss in 3Q 2021)

Mentice AB (publ) to Report First Half, 2023 Results on Jul 20, 2023

Mentice AB (publ), Annual General Meeting, May 11, 2023

Second quarter 2022 earnings released: kr0.71 loss per share (vs kr0.22 loss in 2Q 2021)

Mentice AB (publ) to Report Q4, 2022 Results on Feb 09, 2023

Mentice AB (publ) (OM:MNTC) completed the acquisition of All assets of the Ankyras software suite from Galgo Medical SL.

Mentice AB (publ) (OM:MNTC) agreed to acquire All assets of the Ankyras software suite from Galgo Medical SL for €2.775 million.

First quarter 2022 earnings released: kr0.30 loss per share (vs kr0.50 loss in 1Q 2021)

High number of new directors

Mentice AB (publ) Announces Change of Chairman of Board, Effective December 30, 2022

High number of new directors

Mentice Appoints Jan Grund Pedersen as New Vice President of Strategic Alliances & Business Development

Mentice AB (publ) to Report Fiscal Year 2021 Results on Apr 06, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2021 earnings released: kr0.29 loss per share (vs kr0.014 loss in 3Q 2020)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Chief Financial Officer Elisabet Lund has left the company

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

Less than half of directors are independent

Second quarter 2021 earnings released: kr0.22 loss per share (vs kr0.46 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.50 loss per share (vs kr0.21 loss in 1Q 2020)

New 90-day low: €7.52

Full year 2020 earnings released: kr0.54 loss per share (vs kr1.05 loss in FY 2019)

Revenue misses expectations

Mentice Announces Executive Appointments

Mentice AB (publ) to Report Fiscal Year 2020 Results on Feb 04, 2021

Third quarter 2020 earnings released: kr0.01 loss per share

Revenue misses expectations

Mentice AB (Publ) Announces Nomination Committee

New 90-day low: €7.00

Mentice AB (publ) (OM:MNTC) entered into agreement to acquire substantially all assets of EQIP, Inc. for $0.25 million.

Mentice AB (publ) (OM:MNTC) signed a definitive agreement to acquire Substantial All Assets of Vascular Simulations LLC for $6 million.

Mentice AB (publ) to Report Q2, 2020 Results on Aug 13, 2020

Mentice AB (publ) to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high - €7.36

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri